Lumida
/DVA
⌘K
DaVita Inc

DaVita Inc

DVA
$181.55USD+0.12%+0.22 today

MARKET CAP

11.6B

P/E (TTM)

17.0x

FWD P/E

DAY RANGE

$181 – $184

52W RANGE

$101
$247

AI Summary

Stalk
TrimMedium

DVA remains in a declining phase below its major moving averages, consolidating around the mid-$180s. The medium-term bias stays bearish given the failure to reclaim the 20-day/50-day EMAs, while short-term timing is neutral until a bounce into the EMA zone or breakdown below the $175–$180 base. We will trim into any bounce toward the 20/50 EMA resistance around $182–$184.

  • Q2 revenue $3.55B (+5.2% YoY) and EPS $4.02 vs. $3.88 est.
  • Treatment volumes +56bps YoY driven by improved mortality rates.
  • Revenue per treatment declined ~$2 sequentially, slicing ~$40M revenue.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$11.6B$11.2B$12.1B$12.8B$13.6B
YoY %+0.6%-3.8%+8.6%+5.6%+6.5%
P / Sales1.1x0.6x0.8x1.0x0.6x
EV / Sales2.3x1.9x2.0x2.1x1.8x
Gross Profit, Adj.$3.6B$3.0B$3.8B$4.2B$4.4B
YoY %+2.4%-18.6%+28.8%+10.4%+4.3%
Margin %31.4%26.5%31.5%32.9%32.2%
EV / Gross Profit7.3x7.3x6.2x6.5x5.5x
EBITDA, Adj.$2.5B$1.6B$2.3B$2.7B$2.7B
YoY %+4.7%-34.2%+45.6%+14.2%+1.8%
Margin %21.1%14.4%19.3%20.9%20.0%
EV / EBITDA10.9x13.4x10.1x10.2x8.9x
EBIT$1.8B$879.1M$1.6B$2.0B$2.0B
YoY %+3.5%-50.3%+82.1%+22.1%+2.9%
Margin %15.2%7.9%13.2%15.3%14.7%
EV / EBIT15.1x24.6x14.8x14.0x12.1x
Net Income$978.5M$560.4M$691.5M$936.3M$746.8M
YoY %+26.5%-42.7%+23.4%+35.4%-20.2%
Net Margin8.4%5.0%5.7%7.3%5.5%
EPS (GAAP)$8.90$5.85$7.42$10.73$9.84
YoY %+41.0%-34.3%+26.8%+44.6%-8.3%